Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection

  • Cidara Therapeutics Inc CDTX announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.
  • As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains. 
  • A single dose of CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model compared to a placebo.
  • The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson JNJ, to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza.
  • The interim analysis is based on 56 subjects, with 28 receiving a single dose of CD388 (150 mg) and 28 receiving a placebo. 
  • Treatment with CD388 was generally well-tolerated, with no treatment-emergent adverse events leading to study discontinuation or serious adverse events reported in the interim analysis. 
  • Price Action: CDTX shares are up 12.50% at $1.70 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!